xCass
2021-05-04
Great!
Vaxart shares slide after first-quarter earnings miss
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":106973037,"tweetId":"106973037","gmtCreate":1620086528029,"gmtModify":1634207996509,"author":{"id":3575793577969306,"idStr":"3575793577969306","authorId":3575793577969306,"authorIdStr":"3575793577969306","name":"xCass","avatar":"https://static.tigerbbs.com/4d13a4236fd5fe0391b573daccd86bfc","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Great!</p></body></html>","htmlText":"<html><head></head><body><p>Great!</p></body></html>","text":"Great!","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/106973037","repostId":1121188867,"repostType":4,"repost":{"id":"1121188867","pubTimestamp":1620049912,"share":"https://www.laohu8.com/m/news/1121188867?lang=&edition=full","pubTime":"2021-05-03 21:51","market":"us","language":"en","title":"Vaxart shares slide after first-quarter earnings miss","url":"https://stock-news.laohu8.com/highlight/detail?id=1121188867","media":"seekingalpha","summary":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter res","content":"<p>(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.</p>\n<p><img src=\"https://static.tigerbbs.com/f9684b3617216942a2aa8adfd5d1954d\" tg-width=\"633\" tg-height=\"479\"></p>\n<p>The company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in Japan as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.</p>\n<p>The company saw its R&D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.</p>\n<p>General and administrative expenses also rose to $5.9M from $2M in the prior-year period.</p>\n<p>Vaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.</p>\n<p>The company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.</p>\n<p>Vaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.</p>\n<p>Previously (May 3):Vaxart EPS misses by $0.04, misses on revenue.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vaxart shares slide after first-quarter earnings miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVaxart shares slide after first-quarter earnings miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-05-03 21:51 GMT+8 <a href=https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in ...</p>\n\n<a href=\"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"VXRT":"Vaxart, Inc"},"source_url":"https://seekingalpha.com/news/3689156-vaxart-shares-slide-after-first-quarter-earnings-miss","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1121188867","content_text":"(May 3) Vaxart shares slide over 12% during morning tradingafter the company postedfirst-quarter results that missed Wall Street estimates, owing tohigher research and development costs and a fall in Inavir related royalty revenue.\n\nThe company's quarterly revenue plummeted over 80% to $0.51M, mainly due to a reduction in royalty revenue related to Inavir sales in Japan as a result of abnormally low incidences of seasonal influenza. Revenue missed analysts' estimate by $0.11M.\nThe company saw its R&D expenses rise to $10.1M from $1.5M last year, mainly due to manufacturing and clinical trial expenses related to the COVID-19 and norovirus vaccine candidates.\nGeneral and administrative expenses also rose to $5.9M from $2M in the prior-year period.\nVaxart reported a net loss of $16M, or $0.14 per share, compared to a net loss of $1.3M, or $0.02 per share last year.\nThe company ended the quarter with cash, cash equivalents, and available-for-sale debt securities of $177.3M, compared to $126.9M as of December 31, 2020.\nVaxart also highlighted plans to progress its oral norovirus vaccine program with the initiation of four clinical trials in 2021.\nPreviously (May 3):Vaxart EPS misses by $0.04, misses on revenue.","news_type":1},"isVote":1,"tweetType":1,"viewCount":406,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/106973037"}
精彩评论